Intel the world leader company on technology is going to introduce battery for car ! Good news ,also its a alternative fuel innitiative ,"strategic objective is tackling big problems and turning them into big businesses." He said Intel, with its cash resources, can invest in battery technology and manufacturing to bring down the cost of car batteries, which would drive adoption of plug-in electric cars.
Intel is arguably the world's most important technology company ,Andy Grove former Intel chairman told Rebecca Smith and Don Clark that he has been urging the company to get into the business of making car batteries. Like so many in Silicon Valley, Grove is apparently an electric car booster, and he has been evangelizing car batteries as a potential growth industry—one that he'd like to see Intel get in on the ground floor of.
In an interview with The Wall Street Journal published Friday, Grove said he is urging Intel to invest in battery manufacturing as a way to diversify from its core chip business.
Grove told the Journal that Intel's "strategic objective is tackling big problems and turning them into big businesses." He said Intel, with its cash resources, can invest in battery technology and manufacturing to bring down the cost of car batteries, which would drive adoption of plug-in electric cars.
Batteries are the most expensive component in plug-in electric vehicles, a market being pursued by a few U.S. companies.
General Motor's 2011 Volt is testing batteries from lithium-ion maker A123 Systems. Other U.S. companies include Ener1 and Valence Technology. Notebook battery maker Boston Power also intends to enter the auto market.
But battery makers and analysts say that U.S. manufacturers lack the financial means to meet the anticipated demand of electric cars.
"The technology exists today to put (electric drives) into an automobile," said Ener1 CEO Charles Gassenheimer at last week's Electric Drive Transportation Association's Conference & Exposition. "But it is not doable without the ability to drive down the cost of manufacturing."
Intel has invested in battery technology through its venture capital arm and other energy-related firms. Earlier this year, Intel also spun out SpectraWatt, which intends to lower the cost of manufacturing solar cells.
Grove has become an advocate for government policies that promote plug-in hybrid cars. This summer, he published a manifesto, called "Our Electric Future," in The American magazine, where he called for transitioning the American auto fleet to electricity for national security reasons.
"Because electricity is the stickiest form of energy, and because it is multi-sourced, it will give us the greatest degree of energy resilience. Our nation will be best served if we dedicate ourselves to increasing the amount of our energy that we use in the form of electricity," he wrote.
In a speech at the Plug-in 2008 conference in August, he called for a goal of putting 10 million plug-in vehicles on the road in 10 years.
Over here, or over there?
The WSJ piece leaves the reader with the impression that Grove might like to see Intel making batteries in the US. I'd love a transcript of the interview that underlies the piece, because it's not clear to me if this is the authors' takeaway, or if "let's make them in the US" was a point that Grove himself wanted to emphasize.
I bring this up because Intel doesn't actually make as many chips over here as they used to. Most of the company's sales are overseas (Asia is the biggest market), so that's where a large and growing percentage of its workforce is, as well. The company's pronounced shift in moving jobs abroad has been a sore spot for American Intel employees over the past decade, but I hear that, internally, the Intel top brass makes no bones about the fact that they have no qualms about moving the plants closer to the customers.
But regardless of where Grove wants to see these batteries made, Intel CEO Paul Otellini can't be too happy that his former chairman is exercised enough about this battery scheme that he's talking to the press about it and instigating a news cycle's worth of "should Intel make car batteries?" stories.
Search This Blog
Saturday, December 13, 2008
Wednesday, November 26, 2008
Robotic Surgery effeiency Vs Craze Merkting

Advantages of Robotic Surgery
In today's operating rooms, you'll find two or three surgeons, an anesthesiologist and several nurses, all needed for even the simplest of surgeries. Most surgeries require nearly a dozen people in the room. As with all automation, surgical robots will eventually eliminate the need for some personnel. Taking a glimpse into the future, surgery may require only one surgeon, an anesthesiologist and one or two nurses. In this nearly empty operating room, the doctor sits at a computer console, either in or outside the operating room, using the surgical robot to accomplish what it once took a crowd of people to perform.
The use of a computer console to perform operations from a distance opens up the idea of telesurgery, which would involve a doctor performing delicate surgery miles away from the patient. If the doctor doesn't have to stand over the patient to perform the surgery, and can control the robotic arms from a computer station just a few feet away from the patient, the next step would be performing surgery from locations that are even farther away. If it were possible to use the computer console to move the robotic arms in real-time, then it would be possible for a doctor in California to operate on a patient in New York. A major obstacle in telesurgery has been latency -- the time delay between the doctor moving his or her hands to the robotic arms responding to those movements. Currently, the doctor must be in the room with the patient for robotic systems to react instantly to the doctor's hand movements.
Is Robotic Surgery Better? Or Just Marketing?
Why the U.S. healthcare system (if you want to call it a system, which it isn't) is a mess is obvious. It's mostly because of bureaucratic, inefficient, denial-fixated health insurers—chop out the waste, and escalating costs will come back into line. Considering this albatross as well as various other handicaps, it's amazing that the quality of our healthcare is really good.
Myths, both. Administrative expenses are a relatively small driver of healthcare costs. And the quality of U.S. care not only fails in many respects to measure up to the care delivered in other countries but swings between extremes depending on where you live, the caregiver you see, and the hospital you use. Shannon Brownlee, a visiting scholar at the National Institutes of Health Clinical Center (and a former U.S. News colleague), and oncologist Ezekiel Emanuel, chairman of the center's bioethics department, busted those two myths and three other widespread misconceptions in a well-argued piece in Sunday's Washington Post that is well worth reading.
In their discussion of what is to blame for high and rising costs, they cite technology, among other things, meaning new drugs, new gizmos, new procedures. "Unfortunately," they write, "only a fraction of all that new stuff offers dramatically better outcomes."
That reminded me of a striking admission from Paul Levy, president of Beth Israel Deaconess Medical Center in Boston, who last Friday stated publicly on his blog that the hospital is buying a da Vinci surgical robot for marketing reasons. It costs well over $1 million, not counting its expensive annual care and feeding with new tools and software. All of the hospital's Boston competitors have the robot, and they are drawing referrals away from Beth Israel, which doesn't. "So there you have it," he wrote, his own sentiments clear. "It is an illustrative story of the healthcare system in which we operate."
I'm not sure this is a perfect allegorical example of a pricey technology purchased just because it is new and therefore represents a competitive advantage or, if a hospital doesn't have the technology, the loss of one. It is quite true that the da Vinci robot—which allows a surgeon sitting at a control station to manipulate tiny surgical tools and thus is no more of a "robot" than is a car being driven by a person—has not been shown, with the possible exception of a few specific procedures, to be clinically superior to conventional surgery.
But let's suppose an expensive gadget has been introduced that might be able to do one or more of the following: reduce deaths or complications (saving lives and money), get patients out of the hospital faster (saving money), and get patients back on their feet sooner (making them happier and reducing lost work time). Turning that hypothetical "might" into "yes, it can" or "no, it can't" requires that the gadget be put to use, doesn't it? How can a technology be evaluated without putting hands on, making comparisons with the usual ways, and so on?
Where I have a problem with the Beth Israel situation is that our system is very much driven by marketing. Referring physicians are clients, patients are customers, and every hospital competes for market share. That can mean feeling pressured to have the latest CT scanner or radio-beam therapy or surgical robot. If there aren't enough patients to keep a gadget in use enough to be profitable, get more by hyping the benefits (remember the temporary boom in whole-body scanning a few years ago) or luring patients from other hospitals. Does every hospital in Boston truly need a surgical robot system? Can't expensive technology be pooled?
Subscribe to:
Posts (Atom)